GlaxoSmithKline

GlaxoSmithKline is a global biopharmaceutical company headquartered in London, United Kingdom. Formed through the merger of Glaxo Wellcome and SmithKline Beecham in 2000, it is one of the world's largest pharmaceutical companies. Its portfolio spans prescription medicines, vaccines, and consumer healthcare products, with significant research operations in areas like immunology, oncology, and infectious diseases.

History

The company's origins trace back to several 19th-century businesses, including a London wholesale pharmacy founded by Silas Burroughs and Henry Wellcome that became Burroughs Wellcome & Co.. The modern entity was created by the landmark merger in 2000, uniting the legacies of Glaxo Wellcome—itself formed from the 1995 union of Glaxo and the Wellcome Foundation—and SmithKline Beecham, which resulted from the 1989 merger of SmithKline Beckman and Beecham Group. A major subsequent transaction was the 2015 asset swap with Novartis, which bolstered its vaccines portfolio while divesting its oncology business. In 2022, it completed the demerger of its consumer healthcare division into a new listed company, Haleon.

Operations and products

The company operates through two core global business units: Pharmaceuticals and Vaccines. Its pharmaceutical portfolio includes major respiratory products developed with Innoviva, long-acting HIV treatments, and medicines for immunology and oncology. The vaccines division is one of the world's largest, producing immunizations for diseases such as hepatitis, shingles, and meningitis, with major manufacturing sites in Belgium and Montana. Key best-selling products have historically included Advair for asthma, the HPV vaccine Cervarix, and the bivalent COVID-19 vaccine developed in partnership with Sanofi.

Corporate affairs

The company is publicly traded on the London Stock Exchange and is a constituent of the FTSE 100 Index. Its corporate headquarters are located at GSK House in Brentford, London. Leadership has included notable figures such as former CEO Sir Andrew Witty and current CEO Emma Walmsley, who became the first woman to lead a major pharmaceutical company. It maintains extensive manufacturing and R&D facilities worldwide, with major research centers at Stevenage as part of the UK's Golden Triangle and in Philadelphia's Navy Yard. The company also engages in numerous public-private partnerships, including with the World Health Organization and the Coalition for Epidemic Preparedness Innovations.

Research and development

Research is focused on four core therapeutic areas: infectious diseases, HIV, immunology, and oncology. The company employs a research strategy leveraging advanced technologies like functional genomics and artificial intelligence, often in collaboration with academic institutions such as the University of Cambridge and the Francis Crick Institute. Its R&D pipeline has produced novel mechanisms, such as BCMA-targeted therapies for multiple myeloma. A significant portion of its vaccine research is dedicated to global health challenges, including developing vaccines for malaria and tuberculosis, often funded by organizations like the Bill & Melinda Gates Foundation.

Controversies and legal issues

The company has faced significant legal and ethical challenges, including a record $3 billion settlement in 2012 with the U.S. Department of Justice for unlawful promotion of certain drugs and failure to report safety data. It has also been involved in litigation concerning the alleged side effects of its proton pump inhibitor Zantac, with numerous lawsuits filed in Delaware. In China, a major bribery scandal in 2013 led to a fine from Chinese authorities and damaged its reputation in the market. Furthermore, it has faced criticism and patent disputes over drug pricing and access to medicines, particularly for its HIV treatments in developing countries.

Category:Pharmaceutical companies of the United Kingdom Category:Companies listed on the London Stock Exchange Category:FTSE 100 Index